STOCK TITAN
  1. Home
  2. News
  3. TRVN

Trevena to Present at the JMP Securities Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CHESTERBROOK, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. will participate in a fireside chat at the JMP Securities Life Sciences Conference being held virtually June 16 - 17, 2021.

Presentation Details
Date:Wednesday, June 16, 2021
Time:1:30 pm Eastern Time
Presenter: Carrie Bourdow, President & CEO
Webcast:https://wsw.com/webcast/jmp49/trvn/1718600

A link to the webcast will be available on the Events page of the Investors section of the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar. A replay of the presentation will be archived on the website and available for approximately 30 days following the event. Please contact your JMP Securities representative to schedule virtual one-on-one meetings with Trevena during the conference.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

For more information, please visit www.Trevena.com.

Investor Contact:

Daniel Ferry
LifeSci Advisors
Phone: 617-430-7576
Email: IR@trevena.com

Company Contact:

Sasha Bennett
Director
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409


Stock TRVN logo
Trevena, Inc.

NASDAQ:TRVN

TRVN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TRVN Latest News

Apr 1, 2024
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Dec 28, 2023
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
Dec 27, 2023
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Dec 4, 2023
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
Dec 4, 2023
Trevena Awarded OLINVYK Agreement with Premier, Inc.

TRVN Stock Data

7.56M
18.10M
0.92%
7.95%
0.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CHESTERBROOK

About TRVN

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.